Vector-directed immunity and boosting capacity of VRP-srRNA anti-tumor vaccines

Key Points

• The aim is to examine how often VRP-srRNA vaccines can be given without losing effectiveness due to immune responses against the vector.
• Administered VRP-srRNA vaccines in patient samples and mouse models.
• Measured the immune response through antibody production and T-cell activation.
• Compared immune responses after multiple doses on varying schedules.
• VRP-srRNA vaccination created neutralizing antibodies and T-cell responses.
• A third dose at two-week intervals only slightly increased immunity.
• Previous exposure to VRPs decreased response to a different VRP's transgene.

Abstract